Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
25000 participants
OBSERVATIONAL
2012-03-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objective is to determine the incidence of NPC in the study population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma
NCT06367049
Gene Mutations in Non-Small Cell Lung Cancer Cells
NCT00977509
Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma
NCT06572293
Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue
NCT03048305
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
NCT05682703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The program was conducted in Xiaolan and Minzhong towns of Zhongshan city in 2012.
All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Screening cohort
All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is 30 to 59 years of age inclusive
* Subject has no medical record of nasopharyngeal carcinoma
* ECOG 0-2
* Subject has psychical condition and well consciousness
* Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
Exclusion Criteria
* Subject has medical record of nasopharyngeal carcinoma
* Subject who is not residing in Zhongshan City
30 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongshan People's Hospital, Guangdong, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mingfang Ji
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mingfang Ji, MD
Role: PRINCIPAL_INVESTIGATOR
Zhongshan People's Hospital, Guangdong, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan People's Hospital
Zhongshan, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NPC-PRO-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.